Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$25.65 USD
-0.39 (-1.50%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $25.67 +0.02 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Beam Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,190 | 1,078 | 966 | 300 | 92 |
Receivables | 0 | 0 | 300 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 21 | 15 | 7 | 9 | 3 |
Total Current Assets | 1,211 | 1,093 | 1,273 | 308 | 95 |
Net Property & Equipment | 125 | 116 | 84 | 39 | 24 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 11 | 15 | 14 | 18 | 18 |
Total Assets | 1,460 | 1,342 | 1,474 | 452 | 156 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 9 | 7 | 6 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 112 | 48 | 68 | 18 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 80 | 156 | 131 | 73 | 9 |
Total Current Liabilities | 206 | 224 | 213 | 102 | 29 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 110 | 202 | 262 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3 | 14 | 37 | 8 | 5 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 302 |
Total Liabilities | 478 | 608 | 648 | 206 | 357 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 0 |
Capital Surplus | 2,170 | 1,793 | 1,594 | 643 | 2 |
Retained Earnings | -1,190 | -1,057 | -768 | -398 | -203 |
Other Equity | 1 | -2 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 981 | 733 | 827 | 246 | -201 |
Total Liabilities & Shareholder's Equity | 1,460 | 1,342 | 1,474 | 452 | 156 |
Total Common Equity | 981 | 733 | 827 | 246 | -201 |
Shares Outstanding | 81.50 | 70.40 | 68.10 | 57.90 | NA |
Book Value Per Share | 12.04 | 10.42 | 12.14 | 4.24 | 0.00 |
Fiscal Year End for Beam Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,008 | 1,095 | 1,190 | 1,015 | 1,073 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 21 | 27 | 21 | 24 | 22 |
Total Current Assets | 1,029 | 1,122 | 1,211 | 1,040 | 1,095 |
Net Property & Equipment | 117 | 121 | 125 | 128 | 128 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 7 | 8 | 11 | 11 | 17 |
Total Assets | 1,261 | 1,360 | 1,460 | 1,291 | 1,354 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 3 | 2 | 3 | 7 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 67 | 86 | 112 | 42 | 38 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 93 | 86 | 80 | 163 | 154 |
Total Current Liabilities | 177 | 187 | 206 | 220 | 210 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 110 | 125 | 156 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 77 | 3 | 6 | 13 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 407 | 446 | 478 | 512 | 542 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 2,234 | 2,202 | 2,170 | 2,113 | 2,049 |
Retained Earnings | -1,380 | -1,289 | -1,190 | -1,333 | -1,237 |
Other Equity | -1 | -1 | 1 | -2 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 854 | 913 | 981 | 779 | 812 |
Total Liabilities & Shareholder's Equity | 1,261 | 1,360 | 1,460 | 1,291 | 1,354 |
Total Common Equity | 854 | 913 | 981 | 779 | 812 |
Shares Outstanding | 82.30 | 82.30 | 81.50 | 79.20 | 76.20 |
Book Value Per Share | 10.38 | 11.10 | 12.04 | 9.84 | 10.65 |